AMPH Amphastar Pharmaceuticals Inc.

18.75
+0.12  (+1%)
Previous Close 18.63
Open 18.72
52 Week Low 12.325
52 Week High 22.69
Market Cap $890,353,988
Shares 47,485,546
Float 30,259,436
Enterprise Value $845,176,456
Volume 228,845
Av. Daily Volume 211,446
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Naloxone Intranasal
Opioid overdose
CRL
CRL
CRL announced February 21, 2017.
Primatene Mist (epinephrine inhalation aerosol)
Asthma
CRL
CRL
CRL issued December 27, 2016.

Latest News

  1. RANCHO CUCAMONGA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will participate in an Analyst-Moderated fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference on Thursday, September 10, 2020 at 3:20 p.m. Eastern Time.

    This presentation will be made available with a live webcast and may be accessed by visiting Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation.

    About Amphastar:

    Amphastar is a specialty pharmaceutical…

    RANCHO CUCAMONGA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will participate in an Analyst-Moderated fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference on Thursday, September 10, 2020 at 3:20 p.m. Eastern Time.

    This presentation will be made available with a live webcast and may be accessed by visiting Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 90 days following the presentation.

    About Amphastar:

    Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company's website at www.amphastar.com.

    The Amphastar Pharmaceuticals' logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene®, Amphadase® and Cortrosyn®, are the property of Amphastar Pharmaceuticals, Inc.

    Forward-Looking Statement:

    All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company's expectations regarding future financial performance, backlog, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to its pipeline of product candidates, its share buyback program and other future events, such as the impact of the COVID-19 pandemic and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations and results of operations. These statements are not historical facts but rather are based on Amphastar's historical performance and its current expectations, estimates, and projections regarding Amphastar's business, operations and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control.  Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 16, 2020. In particular, the extent of COVID-19's impact on our business will depend on several factors, including the severity, duration and extent of the pandemic, as well as actions taken by governments, businesses, and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time. You can locate these reports through the Company's website at http://ir.amphastar.com and on the SEC's website at www.sec.gov.  The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause Amphastar's expectations to change.

    Contact:

    Bill Peters

    Chief Financial Officer

    (909) 476-3416

    View Full Article Hide Full Article
  2. RANCHO CUCAMONGA, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2020.

    Second Quarter Highlights

    • Net revenues of $85.8 million for the second quarter
    • GAAP net loss of $0.2 million, or $0.00 per share, for the second quarter
    • Adjusted non-GAAP net income of $7.6 million, or $0.16 per share, for the second quarter

    Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We are pleased with Amphastar's second quarter and the first half of the year so far. Primatene® Mist has been a strong performer for the Company, while our epinephrine multi-dose vial launch continues to gain momentum. Despite…

    RANCHO CUCAMONGA, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2020.

    Second Quarter Highlights

    • Net revenues of $85.8 million for the second quarter
    • GAAP net loss of $0.2 million, or $0.00 per share, for the second quarter
    • Adjusted non-GAAP net income of $7.6 million, or $0.16 per share, for the second quarter

    Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We are pleased with Amphastar's second quarter and the first half of the year so far. Primatene® Mist has been a strong performer for the Company, while our epinephrine multi-dose vial launch continues to gain momentum. Despite the challenges presented by the COVID-19 pandemic, we remain confident, heading into our catalyst-rich second half of the year."

                  
      Three Months Ended  Six Months Ended  
      June 30,  June 30,  
      2020  2019 2020 2019 
               
               
      (in thousands, except per share data) 
    Net revenues $ 85,806  $ 79,047 $ 170,494 $ 158,837 
    GAAP net (loss) income attributable to Amphastar $ (192) $ 47,787 $ 3,757 $ 48,655 
    Adjusted non-GAAP net income attributable to Amphastar* $ 7,610  $ 4,117 $ 15,993 $ 9,002 
    GAAP diluted EPS attributable to Amphastar shareholders $ (0.00) $ 0.96 $ 0.08 $ 0.97 
    Adjusted non-GAAP diluted EPS attributable to Amphastar shareholders* $ 0.16  $ 0.08 $ 0.33 $ 0.18 

    _______________________________

    * Adjusted non-GAAP net income attributable to Amphastar and Adjusted non-GAAP diluted EPS attributable to Amphastar shareholders are non-GAAP financial measures.  Please see the discussion in the section entitled "Non-GAAP Financial Measures" and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.

    Second Quarter Results

                 
      Three Months Ended       
      June 30,  Change 
      2020 2019 Dollars % 
              
              
              
      (in thousands)   
    Net revenues:            
    Primatene® Mist $ 12,468 $ 2,512 $ 9,956   396 %
    Phytonadione   10,689   12,441   (1,752)  (14)%
    Enoxaparin   10,218   9,838   380   4 %
    Lidocaine   7,608   10,082   (2,474)  (25)%
    Naloxone   8,723   7,833   890   11 %
    Epinephrine   6,957   3,139   3,818   122 %
    Other finished pharmaceutical products   24,272   27,890   (3,618)  (13)%
    Total finished pharmaceutical products net revenues $ 80,935 $ 73,735 $ 7,200   10 %
    API   4,871   5,312   (441)  (8)%
    Total net revenues $ 85,806 $ 79,047 $ 6,759   9 %

    Changes in net revenues were primarily driven by:

    • Increased sales of Primatene® Mist primarily resulting from the continued success of our nationwide television, radio, and digital marketing campaign
    • Increased epinephrine sales due to the launch of our newly-approved epinephrine injection, USP 30mg/30mL multiple-dose vial product as well as increased sales of our epinephrine pre-filled syringes
    • Increased naloxone sales due to higher unit volumes
    • Decreased lidocaine sales due to lower demand, largely due to reductions in elective procedures, in which the jelly form of lidocaine is often used, during the COVID-19 pandemic
    • Decreases in other finished pharmaceutical products were driven by reductions in products frequently used in elective procedures including Cortrosyn®, which were partially offset by an increase in sodium bicarbonate as we were able to utilize our new production line approved earlier in the year to meet strong demand
                 
      Three Months Ended       
      June 30,  Change 
      2020  2019  Dollars % 
                
                
                
      (in thousands)   
    Net revenues $ 85,806  $ 79,047  $ 6,759  9%
    Cost of revenues   52,629    46,660    5,969  13%
    Gross profit $ 33,177  $ 32,387  $ 790  2%
    as % of net revenues  39%  41%      

    Changes in cost of revenues and the resulting decrease to gross margin were primarily driven by:

    • Increase in inventory reserves including a $3.6 million reserve for crude heparin purchases and commitments at our Chinese subsidiary, Amphastar Nanjing Pharmaceuticals, Inc.
    • Increased sales of Primatene® Mist and the launch of epinephrine injection multiple-dose vial, both of which have higher margins, partially offset the inventory reserves
                 
      Three Months Ended       
      June 30,  Change 
      2020 2019 Dollars % 
              
              
              
      (in thousands)   
    Selling, distribution and marketing $ 4,026 $ 2,992 $ 1,034  35%
    General and administrative   15,924   12,426   3,498  28%
    Research and development   16,149   15,996   153  1%
    • Marketing and distribution expenses increased primarily related to Primatene® Mist, including the cost of a national digital, television, radio and digital marketing campaign, which began in July 2019
    • General and administrative expenses increased primarily due to the separation agreement entered into with a former executive, in which we incurred an expense of $4.9 million relating to cash compensation and share-based compensation expense
    • Research and development expenses increased primarily at our ANP subsidiary
                 
      Three Months Ended       
      June 30,  Change 
      2020 2019 Dollars % 
              
              
      (in thousands)   
    Non-operating income (expense), net $ 1,418 $ 60,120 $ (58,702) NM 
    • In June 2019, we recognized a gain of $59.9 million relating to the settlement of our patent and antitrust litigation with Momenta Pharmaceuticals, Inc. and Sandoz Inc.

    Cash flow provided by operating activities for the six months ended June 30, 2020, was $31.6 million.

    Impact of COVID-19

    The increase in sales of Primatene® Mist and certain hospital products as a result of the COVID-19 pandemic experienced towards the end of the first quarter continued into the early part of the second quarter of 2020. We also noticed a decline in demand for certain products such as Cortrosyn® and lidocaine, which are frequently used in elective procedures. The Company has not experienced any significant negative impacts on its cash flows or operations as a result of the COVID-19 pandemic. All of the Company's production facilities continued to operate during the quarter as they had prior to the COVID-19 pandemic with very little change, other than for enhanced safety measures intended to prevent the spread of the virus. It is not possible at this time to estimate the complete impact that the COVID-19 pandemic could have on our business, as the impact will depend on future developments of the pandemic, which are highly uncertain and cannot be predicted.

    Share Buyback Program

    On August 4, 2020, the Company's Board of Directors authorized an increase of $20 million to the Company's share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company's equity compensation programs.

    Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions, or other means, as determined by the Company's management and in accordance with the requirements of the Securities and Exchange Commission and applicable laws.

    The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions.

    Pipeline Information

    The Company currently has five ANDAs filed with the FDA targeting products with a market size of approximately $1.7 billion, three biosimilar products in development targeting products with a market size of approximately $13 billion, and nine generic products in development targeting products with a market size of approximately $12 billion. This market information is based on IQVIA data for the 12 months ended June 30, 2020. The Company is currently developing four proprietary products, including a new drug application for intranasal naloxone.

    Amphastar's Chinese subsidiary, ANP, currently has 14 Drug Master Files, or DMFs, on file with the FDA and is developing several additional DMFs.

    Company Information

    Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products.  Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.  More information and resources are available at www.amphastar.com.

    Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, Primatene®, Amphadase® and Cortrosyn®, are the property of Amphastar.

    Non-GAAP Financial Measures

    To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) attributed to Amphastar and (ii) Adjusted non-GAAP diluted EPS attributed to Amphastar's shareholders, which exclude amortization expense, share-based compensation, impairment charges, executive severance expense, and legal settlements, in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance because the Company's management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.

    Conference Call Information

    The Company will hold a conference call to discuss its financial results today, August 6, 2020, at 2:00 p.m. Pacific Time.

    To access the conference call, dial toll-free (800) 708-4540 five minutes before the conference. The passcode for the conference call is 49844225.

    The call can also be accessed on the Investors page on the Company's website at www.amphastar.com

    Forward-Looking Statements

    All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company's expectations regarding future financial performance, backlog, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to its pipeline of product candidates, its share buyback program and other future events, such as the impact of the COVID-19 pandemic and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations and results of operations. These statements are not historical facts but rather are based on Amphastar's historical performance and its current expectations, estimates, and projections regarding Amphastar's business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control.  Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in the Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020. In particular, the extent of COVID-19's impact on our business will depend on several factors, including the severity, duration and extent of the pandemic, as well as actions taken by governments, businesses, and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time. You can locate these reports through the Company's website at http://ir.amphastar.com and on the SEC's website at www.sec.gov.  The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause Amphastar's expectations to change.

    Contact Information: 

    Amphastar Pharmaceuticals, Inc.

    Bill Peters

    Chief Financial Officer

    (909) 980-9484



    Table I

    Amphastar Pharmaceuticals, Inc.

    Condensed Consolidated Statement of Operations

    (Unaudited; in thousands, except per share data)

                  
      Three Months Ended  Six Months Ended  
      June 30,  June 30,  
      2020  2019  2020  2019  
                  
    Net revenues $ 85,806  $ 79,047  $ 170,494  $ 158,837  
    Cost of revenues   52,629    46,660    100,494    95,547  
    Gross profit   33,177    32,387    70,000    63,290  
                  
    Operating expenses:             
    Selling, distribution, and marketing   4,026    2,992    7,320    6,133  
    General and administrative   15,924    12,426    26,670    28,753  
    Research and development   16,149    15,996    31,452    30,603  
    Total operating expenses   36,099    31,414    65,442    65,489  
                  
    (Loss) income from operations   (2,922)   973    4,558    (2,199) 
                  
    Non-operating income (expenses), net   1,418    60,120    (257)   59,659  
                  
    (Loss) income before income taxes   (1,504)   61,093    4,301    57,460  
    Income tax (benefit) provision   (75)   14,173    2,205    12,694  
                  
    Net (loss) income $ (1,429) $ 46,920  $ 2,096  $ 44,766  
                  
    Net loss attributable to non-controlling interests $ (1,237) $ (867) $ (1,661) $ (3,889) 
                  
    Net (loss) income attributable to Amphastar $ (192) $ 47,787  $ 3,757  $ 48,655  
                  
    Net (loss) income per share attributable to Amphastar shareholders:             
    Basic $ (0.00) $ 1.01  $ 0.08  $ 1.04  
    Diluted $ (0.00) $ 0.96  $ 0.08  $ 0.97  
                  
    Weighted-average shares used to compute net (loss) income per share attributable to Amphastar shareholders:             
    Basic   46,753    47,107    46,581    46,925  
    Diluted   46,753    49,894    48,458    50,155  
                      

    Table II

    Amphastar Pharmaceuticals, Inc.

    Condensed Consolidated Balance Sheets

    (Unaudited; in thousands, except share data)

           
      June 30,  December 31, 
      2020  2019 
      (unaudited)   
    ASSETS      
    Current assets:      
    Cash and cash equivalents $ 87,388  $ 73,685 
    Restricted cash   1,865    1,865 
    Short-term investments   11,101    11,675 
    Restricted short-term investments   2,200    2,290 
    Accounts receivable, net   49,862    45,376 
    Inventories   104,726    110,501 
    Income tax refunds and deposits   682    311 
    Prepaid expenses and other assets   8,997    9,538 
    Total current assets   266,821    255,241 
           
    Property, plant, and equipment, net   238,236    233,856 
    Finance lease right-of-use assets   774    887 
    Operating lease right-of-use assets   17,086    18,805 
    Goodwill and intangible assets, net   40,271    41,153 
    Other assets   12,635    11,156 
    Deferred tax assets   24,235    25,873 
    Total assets $ 600,058  $ 586,971 
           
    LIABILITIES AND STOCKHOLDERS' EQUITY      
    Current liabilities:      
    Accounts payable and accrued liabilities $ 75,385  $ 77,051 
    Income taxes payable   2,345    2,042 
    Current portion of long-term debt   12,075    7,741 
    Current portion of operating lease liabilities   3,481    3,175 
    Total current liabilities   93,286    90,009 
           
    Long-term reserve for income tax liabilities   3,425    3,425 
    Long-term debt, net of current portion   34,622    39,394 
    Long-term operating lease liabilities, net of current portion   14,530    16,315 
    Deferred tax liabilities   760    867 
    Other long-term liabilities   10,998    9,433 
    Total liabilities   157,621    159,443 
    Commitments and contingencies      
    Stockholders' equity:      
    Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding      
    Common stock: par value $0.0001; 300,000,000 shares authorized; 54,372,275 and 47,494,909 shares issued and outstanding as of June 30, 2020 and 52,495,483 and 46,576,968 shares issued and outstanding as of December 31, 2019, respectively   5    5 
    Additional paid-in capital   396,841    367,305 
    Retained earnings   120,127    116,370 
    Accumulated other comprehensive loss   (5,173)   (4,687)
    Treasury stock   (114,119)   (97,627)
    Total Amphastar Pharmaceuticals, Inc. stockholders' equity   397,681    381,366 
    Non-controlling interests   44,756    46,162 
    Total equity   442,437    427,528 
    Total liabilities and stockholders' equity $ 600,058  $ 586,971 
             

    Table III

    Amphastar Pharmaceuticals, Inc.

    Reconciliation of Non-GAAP Measures

    (Unaudited; in thousands, except per share data)

                 
      Three Months Ended  Six Months Ended
      June 30,  June 30, 
      2020  2019  2020  2019 
                 
    GAAP net (loss) income $ (1,429) $ 46,920  $ 2,096  $ 44,766 
    Adjusted for:            
    Intangible amortization   251    256    509    526 
    Share-based compensation   4,194    4,032    9,476    8,706 
    Impairment of long-lived assets   16    46    30    183 
    Expense related to executive separation agreement   4,869    —    4,869    — 
    Gain on litigation settlement   —    (59,900)   —    (59,900)
    Income tax (benefit) provision on pre-tax adjustments   (1,445)   11,955    (2,449)   11,020 
    Non-GAAP net income $ 6,456  $ 3,309  $ 14,531  $ 5,301 
                 
    Non-GAAP net loss attributable to non-controlling interests $ (1,154) $ (808) $ (1,462) $ (3,701)
                 
    Non-GAAP net income attributable to Amphastar $ 7,610  $ 4,117  $ 15,993  $ 9,002 
                 
    Non-GAAP net income per share attributable to Amphastar shareholders:            
    Basic $ 0.16  $ 0.09  $ 0.34  $ 0.19 
    Diluted $ 0.16  $ 0.08  $ 0.33  $ 0.18 
                 
    Weighted-average shares used to compute non-GAAP net income per share attributable to Amphastar shareholders:            
    Basic   46,753    47,107    46,581    46,925 
    Diluted   48,668    49,894    48,458    50,155 



                          
      Three Months Ended June 30, 2020
                     
        Selling, General  Research Non-operating Income Non-controlling
      Cost of  distribution and and income  tax provision interest
      revenue and marketing administrative development (expense), net (benefit) adjustment
    GAAP $ 52,629  $ 4,026  $ 15,924  $ 16,149  $ 1,418 $ (75) $ (1,237)
    Intangible amortization   (217)   —    (34)   —    —   —    11 
    Share-based compensation   (970)   (123)   (2,733)   (368)   —   —    86 
    Impairment of long-lived assets   (3)   —    (13)   —    —   —    6 
    Expense related to executive separation agreement   —    —    (4,869)   —    —   —    — 
    Income tax provision (benefit) on pre-tax adjustments   —    —    —    —    —   1,445    (20)
    Non-GAAP $ 51,439  $ 3,903  $ 8,275  $ 15,781  $ 1,418 $ 1,370  $ (1,154)

    Reconciliation of Non-GAAP Measures (continued)

                          
      Three Months Ended June 30, 2019
                     
        Selling, General  Research Non-operating Income Non-controlling
      Cost of  distribution and and income  tax provision interest
      revenue and marketing administrative development (expense), net (benefit) adjustment
    GAAP $ 46,660  $ 2,992  $ 12,426  $ 15,996  $ 60,120  $ 14,173  $ (867)
    Intangible amortization   (223)   —    (33)   —    —    —    11 
    Share-based compensation   (959)   (95)   (2,648)   (330)   —    —    56 
    Impairment of long-lived assets   (43)   —    (3)   —    —    —    1 
    Gain on litigation settlement   —    —    —    —    (59,900)   —    — 
    Income tax (benefit) provision on pre-tax adjustments   —    —    —    —    —    (11,955)   (9)
    Non-GAAP $ 45,435  $ 2,897  $ 9,742  $ 15,666  $ 220  $ 2,218  $ (808)



                          
      Six Months Ended June 30, 2020
                     
        Selling, General  Research Non-operating Income Non-controlling
      Cost of  distribution and and income  tax provision interest
      revenue and marketing administrative development (expense), net (benefit) adjustment
    GAAP $ 100,494  $ 7,320  $ 26,670  $ 31,452  $ (257) $ 2,205 $ (1,661)
    Intangible amortization   (441)   —    (68)   —    —    —   22 
    Share-based compensation   (2,329)   (230)   (5,952)   (965)   —    —   213 
    Impairment of long-lived assets   (13)   —    (17)   —    —    —   7 
    Expense related to executive separation agreement   —    —    (4,869)   —    —    —   — 
    Income tax provision (benefit) on pre-tax adjustments   —    —    —    —    —    2,449   (43)
    Non-GAAP $ 97,711  $ 7,090  $ 15,764  $ 30,487  $ (257) $ 4,654 $ (1,462)



                          
      Six Months Ended June 30, 2019
                     
        Selling, General  Research Non-operating Income Non-controlling
      Cost of  distribution and and income  tax provision interest
      revenue and marketing administrative development (expense), net (benefit) adjustment
    GAAP $ 95,547  $ 6,133  $ 28,753  $ 30,603  $ 59,659  $ 12,694  $ (3,889)
    Intangible amortization   (453)   —    (73)   —    —    —    22 
    Share-based compensation   (2,238)   (189)   (5,439)   (840)   —    —    150 
    Impairment of long-lived assets   (65)   —    (12)   (106)   —    —    49 
    Gain on litigation settlement   —    —    —    —    (59,900)   —    — 
    Income tax (benefit) provision on pre-tax adjustments   —    —    —    —    —    (11,020)   (33)
    Non-GAAP $ 92,791  $ 5,944  $ 23,229  $ 29,657  $ (241) $ 1,674  $ (3,701)
    View Full Article Hide Full Article
  3. RANCHO CUCAMONGA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2020 ended June 30, 2020, after the market closes on Thursday, August 6th, 2020, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

    To access the conference call, dial toll free (800) 708-4540, five minutes before the conference. The passcode for the conference call is 49844225.

    The call can also be accessed on the Investors page on the Company's website www.amphastar.com.

    Amphastar is a specialty pharmaceutical company that primarily develops, manufactures, markets, and sells generic and proprietary injectable and inhalation…

    RANCHO CUCAMONGA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2020 ended June 30, 2020, after the market closes on Thursday, August 6th, 2020, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

    To access the conference call, dial toll free (800) 708-4540, five minutes before the conference. The passcode for the conference call is 49844225.

    The call can also be accessed on the Investors page on the Company's website www.amphastar.com.

    Amphastar is a specialty pharmaceutical company that primarily develops, manufactures, markets, and sells generic and proprietary injectable and inhalation products, including products with high technical barriers to market entry. Most of the Company's products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.

    Forward Looking Statements

    All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company's expectations regarding future financial performance, backlog, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to its pipeline of product candidates, its share buyback program and other future events, such as the impact of the COVID-19 pandemic and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations and results of operations. These statements are not historical facts but rather are based on Amphastar's historical performance and its current expectations, estimates, and projections regarding Amphastar's business, operations and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control.  Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 16, 2020. In particular, the extent of COVID-19's impact on our business will depend on several factors, including the severity, duration and extent of the pandemic, as well as actions taken by governments, businesses, and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time. You can locate these reports through the Company's website at http://ir.amphastar.com and on the SEC's website at www.sec.gov.  The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause Amphastar's expectations to change.



    Contact:

    William J. Peters

    Chief Financial Officer

    (909) 980-9484

    View Full Article Hide Full Article
  4. RANCHO CUCAMONGA, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will be presenting at BMO Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 1:00 p.m. Eastern Time.

    This presentation will be made available with a live webcast and may be accessed by visiting Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 90 days following the presentation.

    About Amphastar:

    Amphastar is a specialty pharmaceutical company that focuses primarily on…

    RANCHO CUCAMONGA, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will be presenting at BMO Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 1:00 p.m. Eastern Time.

    This presentation will be made available with a live webcast and may be accessed by visiting Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 90 days following the presentation.

    About Amphastar:

    Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company's website at www.amphastar.com.

    The Amphastar Pharmaceuticals' logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene®, Amphadase® and Cortrosyn®, are the property of Amphastar Pharmaceuticals, Inc.

    Forward-Looking Statement:

    All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company's expectations regarding future financial performance, backlog, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to its pipeline of product candidates, its share buyback program and other future events, such as the impact of the COVID-19 pandemic and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations and results of operations. These statements are not historical facts but rather are based on Amphastar's historical performance and its current expectations, estimates, and projections regarding Amphastar's business, operations and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control.  Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 16, 2020. In particular, the extent of COVID-19's impact on our business will depend on several factors, including the severity, duration and extent of the pandemic, as well as actions taken by governments, businesses, and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time. You can locate these reports through the Company's website at http://ir.amphastar.com and on the SEC's website at www.sec.gov.  The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause Amphastar's expectations to change.

    Contact:

    Bill Peters

    Chief Financial Officer

    (909) 476-3416

    View Full Article Hide Full Article
  5. RANCHO CUCAMONGA, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will be presenting at the Raymond James Virtual 2020 Human Healthcare Innovation Conference on Thursday, June 18, 2020 at 11:40 a.m. Eastern Time.

    This presentation will be made available with a live webcast and may be accessed by visiting Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 90 days following the presentation.

    About Amphastar:

    Amphastar is a specialty pharmaceutical company that…

    RANCHO CUCAMONGA, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will be presenting at the Raymond James Virtual 2020 Human Healthcare Innovation Conference on Thursday, June 18, 2020 at 11:40 a.m. Eastern Time.

    This presentation will be made available with a live webcast and may be accessed by visiting Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 90 days following the presentation.

    About Amphastar:

    Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company's website at www.amphastar.com.

    The Amphastar Pharmaceuticals' logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene®, Amphadase® and Cortrosyn®, are the property of Amphastar Pharmaceuticals, Inc.

    Forward-Looking Statement:

    All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company's expectations regarding future financial performance, backlog, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to its pipeline of product candidates, its share buyback program and other future events, such as the impact of the COVID-19 pandemic and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations and results of operations. These statements are not historical facts but rather are based on Amphastar's historical performance and its current expectations, estimates, and projections regarding Amphastar's business, operations and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 16, 2020. In particular, the extent of COVID-19's impact on our business will depend on several factors, including the severity, duration and extent of the pandemic, as well as actions taken by governments, businesses, and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time. You can locate these reports through the Company's website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause Amphastar's expectations to change.

    Contact:

     Bill Peters

    Chief Financial Officer

    (909) 476-3416
    View Full Article Hide Full Article
View All Amphastar Pharmaceuticals Inc. News